NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Provided By PR Newswire

Last update: Sep 4, 2025

Financing at 40% premium to market price provides near-term bridge to anticipated milestones

CAMBRIDGE, Mass., Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a definitive agreement with a single investor for a $500,000 private placement of ordinary shares.